Vistagen Announces Results of Successful U.S. Phase 1 Study of Itruvone (PH10), Enabling U.S. Phase 2B Development for Treatment of Major Depressive Disorder

Vistagen has announced the results of a successful US Phase 1 study of Itruvone (PH10), which enables the drug's development for treating major depressive disorder. The U.S. Phase 1 clinical trial was a randomized, double-blind, placebo-controlled clinical study investigating the safety and tolerability of a single dose and multiple doses of itruvone nasal spray in healthy adult subjects. The po..